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Despite the presence of effective treatment, tuberculosis (TB) remains 
a significant challenge globally. In 2017, ~1.3 million deaths among 
HIV-negative people and a further 300 000 deaths among HIV-positive 
people were attributed to the disease worldwide.[1] The mortality 
rate in patients with active pulmonary TB requiring mechanical 
ventilation ranges from 26% to 83%.[2] Prognostic evaluation using 
severity-of-illness scores may be useful in developing strategies to 
improve outcome in the intensive care unit (ICU). However, the ideal 
prognostic score remains elusive. The Acute Physiology and Chronic 
Health Evaluation II (APACHE II) score, frequently used to estimate 
the probability of hospital mortality for patients admitted to the ICU, 
is completed 24 hours following ICU admission and has not been 
validated in the emergency department.[3]
We previously retrospectively validated a 6-point severity-of-
illness score aimed at identifying ICU patients at risk of dying of 
TB.[4] The parameters included septic shock, HIV infection with a 
CD4 count <200 cells/µL, renal dysfunction (creatinine >140 µmol/L 
(male) or >120 µmol/L (female)), arterial oxygen partial pressure 
to fractional inspired oxygen (P/F) ratio <200 mmHg, a chest 
radiograph demonstrating diffuse parenchymal infiltrates, and no 
TB treatment on admission.[4] The scores were significantly lower in 
survivors compared with non-survivors (mean (standard deviation 
(SD)) 2.27 (1.47) v. 3.58 (1.08); p<0.001). Moreover, a score of ≥3 
was associated with significantly higher mortality than a score of 
<3 (64.6% v. 20.0%; odds ratio (OR) 7.29; 95% confidence interval 
(CI) 2.64 - 20.18; p<0.001).
Objectives
To prospectively validate the severity-of-illness scoring system 
in patients with TB requiring intensive care, and secondarily to 
potentially refine and simplify the score in order to expand its clinical 
utility.
Methods
Study population and setting
All adult patients (aged ≥18 years) admitted to the medical 
ICU at Tygerberg Hospital, Cape Town, South Africa (SA), with 
the diagnosis of confirmed active TB were enrolled. Tygerberg 
Hospital, a 1 380-bed facility, is one of two referral centres in Cape 
Town rendering a tertiary service to a population of ~1.5 million 
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Background. We previously retrospectively validated a 6-point severity-of-illness score aimed at identifying patients at risk of dying of 
tuberculosis (TB) in the intensive care unit (ICU). Parameters included septic shock, HIV infection with a CD4 count <200 cells/µL, renal 
dysfunction, a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (P/F) <200 mmHg, a chest radiograph demonstrating 
diffuse parenchymal infiltrates, and no TB treatment on admission.
Objectives. To prospectively validate the severity-of-illness scoring system in patients with TB requiring intensive care, and to refine and 
simplify the score in order to expand its clinical utility.
Methods. We performed a prospective observational study with a planned post hoc retrospective analysis, enrolling all adult patients with 
confirmed TB admitted to the medical ICU of a tertiary hospital in Cape Town, South Africa, from 1 February 2015 to 31 July 2018. The 
admission data of all adult patients with TB requiring admission to the ICU were used to calculate the 6-point severity-of-illness score and 
a refined 4-point score (based on the planned post hoc analysis). Descriptive statistics and χ2 or Fisher’s exact tests (where indicated) were 
performed on dichotomous categorical variables, and t-tests on continuous data. Patients were categorised as hospital survivors or non-
survivors.
Results. Forty-one of 78 patients (52.6%) died. The 6-point scores of non-survivors were higher than those of survivors (mean (standard 
deviation (SD)) 3.5 (1.3) v. 2.7 (1.2); p=0.01). A score ≥3 v. <3 was associated with increased mortality (64.0% v. 32.1%; odds ratio (OR) 3.75; 
95% confidence interval (CI) 1.25 - 10.01; p=0.01). Post hoc, a P/F ratio <200 mmHg and no TB treatment on admission failed to predict 
mortality, whereas any immunosuppression did. A revised 4-point score (septic shock, any immunosuppression, acute kidney injury and 
lack of lobar consolidation) demonstrated higher scores in non-survivors than survivors (mean (SD) 2.8 (1.1) v. 1.6 (1.1); p<0.001). A score 
≥3 v. ≤2 was associated with increased mortality (78.4% v. 29.3%; OR 8.76; 95% CI 3.12 - 24.59; p<0.001).
Conclusions. The 6-point severity-of-illness score identified patients at increased risk of death. We were able to derive and retrospectively 
validate a simplified 4-point score with superior predictive power.
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people. In 2018, the incidence rate of TB in SA was ~520/100 000 
population.[1]
Study design
This prospective observational cohort study was conducted from 
1 February 2015 to 31 July 2018 and was approved by the Stellenbosch 
University Health Research Ethics Committee (ref. no. N14/10/). 
Patients were considered to have active TB if at least two of the 
following criteria were met: (i) smear positive for acid-fast bacilli 
or Xpert MTB/RIF (Cepheid, SA) on sputum, tracheal aspirate, or 
any other clinical specimen; (ii) culture positive for Mycobacterium 
tuberculosis on sputum, tracheal aspirate or any other clinical 
specimen; (iii) histopathological identification of TB granuloma on 
biopsied tissues; (iv) strong clinical suspicion of active TB; (v) strong 
radiological evidence of active TB; and (vi) pleural fluid with a 
lymphocyte predominance (>75% lymphocytes and/or lymphocyte/
neutrophil ratio >0.75) with adenosine deaminase >40  IU/L. 
A strong clinical suspicion of active TB required at least two of four 
constitutional symptoms (loss of weight with accompanying fever, 
night sweats, productive cough, and loss of appetite for >2 weeks) as 
well as known TB contact or a history of previous pulmonary TB. 
Positive cultures were identified as M. tuberculosis and tested for 
susceptibility to rifampicin and isoniazid using the MTBDRplus line 
probe assay (Hain LifeSciences, Germany). The study included patients 
with both drug-susceptible TB and drug-resistant TB (DR-TB).
Clinical data, laboratory tests, imaging and related 
investigations
Patient demographics, comorbid disease, the presence of septic shock, 
the degree of hypoxaemia utilising the P/F ratio and the presence of 
TB treatment were documented. Laboratory investigations included 
the white blood cell count, platelet count, serum haemoglobin, 
serum albumin, C-reactive protein, serum creatinine and alanine 
aminotransferase. Absolute CD4 counts were measured in HIV-
positive patients. The admission chest radiograph of each patient 
was reviewed by two pulmonologists independently, who were 
blinded to the clinical data. The chest radiographs were classified as 
follows: (i)  multilobar/diffuse involvement; (ii) lobar consolidation; 
(iii)  cavi tation; (iv)  pleural effusion; (v) isolated lymphadenopathy; 
or (vi)  normal. The APACHE II score was calculated after the first 
24 hours in the ICU. The 6-point severity-of-illness score for each study 
participant was determined from data obtained on ICU admission.
Management and complications
All patients were managed according to local guidelines and received 
maximal supportive therapy. The standard combination anti-TB 
treatment regimen was used unless significant renal or hepatic 
impairment or confirmed drug resistance was present.[5] Standard 
diagnostic criteria for septic shock, renal failure and acute respiratory 
distress syndrome (ARDS) were employed.[6-8]
Statistical analysis
Data were analysed using SPSS 17.0 (IBM, USA). Descriptive statistics 
and χ2 or Fisher’s exact tests (where indicated) were performed on 
dichotomous categorical variables, and t-tests on continuous data. 
Patients were categorised as hospital survivors or non-survivors. Based 
on our previous study, we estimated that a sample size of ~80 patients 
was needed to validate the original 6-point severity-of-illness score.[4]
Post hoc analyses
A planned post hoc analysis was performed to assess the significance 
of various parameters used in the severity-of-illness score as well as 
other markers of mortality and potentially derive a simplified (and 
potentially more practical) score with equal or higher predictive 
power. The more recently described Kidney Disease: Improving 
Global Outcomes (KDIGO) Clinical Practice Guideline for Acute 




During the study period, a total of 78 TB patients (mean (standard 
deviation (SD)) age 36.1 (14.4) years, n=40 males) were admitted to 
the medical ICU, all of whom were included in the study. The majority 
of the patients (n=76; 97%) had active pulmonary TB. Eleven of these 
patients had disseminated disease. Two patients had evidence of 
extrapulmonary TB exclusively. Extrapulmonary involvement in all 
patients, including those with concomitant pulmonary involvement, 
included pleural (n=16), pericardial (n=4) and neurological (n=5) 
disease, TB lymphadenitis (n=2) and abdominal TB (n=5). Seventeen 
patients (21.8%) were on TB treatment at the time of admission. 
Twenty-four patients (30.8%) were HIV-infected, of whom 17 had 
a CD4 count <200 cells/µL. Other forms of immunocompromised 
states included diabetes mellitus (n=10) and treatment with immuno-
suppressive drugs (n=3).
The mean (range) duration of ICU admission was 7.4 (1 - 22) 
days. The most common indication for admission directly related to 
TB was acute respiratory failure (n=51; 65.4%). ARDS was present 
in 5 survivors and 6 non-survivors in this group of patients. Other 
indications included a decreased level of consciousness (n=7), upper 
airway obstruction (n=1) and cardiac tamponade (n=1). Eighteen 
patients were admitted for concomitant disease unrelated to TB.
Tracheal aspirates were obtained from all patients with presumed 
pulmonary TB, and the diagnosis was supported by a positive Xpert MTB/
RIF in all but 6 patients. Three patients were rifampicin resistant (DR-
TB). The diagnosis of TB in the absence of direct microbiological proof 
or a positive Xpert MTB/RIF was based on a high clinical probability, 
combined with radiological evidence alone (n =2), radiological and 
pleural fluid analysis (n=2), radiological and cerebrospinal fluid (CSF) 
fluid analysis (n=1) and CSF analysis alone (n=1).
Twenty-one patients died in the ICU (ICU mortality 26.9%) 
and a further 20 patients died in hospital following ICU discharge 
(in-hospital mortality 52.5%).
Predictors of mortality and the performance of the 
6-point score
The clinical, radiological and laboratory data of survivors and 
non-survivors are summarised in Tables 1 - 3. Of note is the fact 
that other forms of immunosuppression were strongly associated 
with increased mortality, as was renal impairment. Septic shock 
was a strong predictor of mortality (OR 5.21; 95% CI 1.97 - 9.33). 
Patients with lobar consolidation had an increased likelihood of 
survival. Thrombocytopenia and hypolbuminaemia were associated 
with increased mortality, as was high serum creatinine. The 6-point 
severity of illness score predicted mortality (Table 4). A score of 
≥3 was associated with a higher mortality rate than a score of <3 
(p=0.007 and OR 3.75; 95% CI 1.41 - 10.01).
Post hoc analyses
In view of the lack of a significant association with mortality of 
both P/F <200  mmHg and absence of TB treatment on admission, 
in conjunction with the strong association with other (non-HIV) 
immunocompromised states and the more recently described KDIGO 
guidelines for acute kidney injury, we proposed a refined score, 
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utilising 4 parameters: (i) septic shock; (ii) any immunocompromised 
state; (iii) acute kidney injury; and (iv) chest radiography not 
compatible with lobar consolidation. We subsequently retrospectively 
applied the 4-point score to the current cohort’s admission data and 
found even higher discrimination (Table 5, Fig. 1). The 4-point scores 
of non-survivors were significantly higher than those of survivors 
(mean (SD) 2.8 (1.1) v. 1.6 (1.1); p<0.001). A score ≥3 v. ≤2 was 
associated with significantly increased mortality (78.4% v. 29.3%; 
OR 8.76; 95% CI 3.12 - 24.59; p<0.001).
Discussion
In this prospective study, we found that the proposed 6-point 
severity-of-illness score accurately identified critically ill patients 
at increased risk of dying of TB. A score of ≥3 was associated with 
a higher mortality rate, with an OR of 3.75 (p=0.007). Moreover, 
we were able to refine and simplify the score. The refined score 
had even higher predictive power: a score of ≥3 v. ≤2 was strongly 
associated with increased mortality (78.4% v. 29.3%; OR 8.76; 
p<0.001).







(N=41) OR (95% CI) p-value 
Sex (female), n 38 19 19 0.82 (0.34 - 1.99) 0.64
Age (years), mean (SD) 36.1 (14.4) 33.0 (11.8) 38.8 (16.1) NA 0.07
APACHE II, mean (SD) 23.8 (8.0) 21.2 (7.4) 26.3 (7.8) NA 0.01
Extrapulmonary TB, n 13 4 9 2.32 (0.65 - 8.30) 0.19
HIV positive, n 24 11 13 1.10 (0.42 - 2.88) 1
HIV with CD4 <200 cells/µL, n 17 7 10 1.38 (0.47 - 4.11) 0.56
Other immunosuppression, n 13 1 12 14.8 (1.83 - 121.38) 0.002
TB treatment on ICU admission, n 17 11 6 0.41 (0.13 - 1.24) 0.18
OR = odds ratio; CI = confidence interval; SD = standard deviation; NA = not available; APACHE II = Acute Physiology and Chronic Health Evaluation II; TB = tuberculosis;  
ICU = intensive care unit.







(N=41), n OR (95% CI) p-value 
Septic shock,* 37 10 27 5.21 (1.97-13.75) <0.01
Renal impairment,† 28 8 20 3.48 (1.28-9.33) 0.02
ARDS 11 5 6 0.91 (0.25 - 3.28) 1
P/F ratio <200 mmHg 34 19 15 0.55 (0.22 - 1.35) 0.28
Radiology
Multilobar involvement‡ 69 31 38 2.45 (0.57 - 10.61) 0.29
Lobar consolidation 7 6 1 0.13 (0.01 - 1.13) 0.05
Cavitation 19 12 7 0.43 (0.15 - 1.25) 0.19
Pleural effusion 16 5 11 2.35 (0.73 - 7.55) 0.17
Isolated lymphadenopathy 0 0 0 NA NA
Normal 2 0 2 NA NA
OR = odds ratio; CI = confidence interval; ARDS = acute respiratory distress syndrome; P/F ratio = arterial partial oxygen pressure to inspired fractional oxygen concentration ratio;  
NA = not available.
*Systolic blood pressure <90 mmHg, 40 mmHg drop from baseline; lactate >4 mmol/L.
†Creatinine >140 µmol/L (male) or >120 µmol/L (female).
‡Includes diffuse interstitial infiltrates, miliary tuberculosis and multilobar consolidation.







(n=41), mean (SD) p-value 
CD4 count (cells/µL) 600 - 1 500 160 (181) 176 (134) 145 (221) 0.68
P/F ratio (mmHg) >300 216 (100) 220 (109) 229 (91) 0.79
White cell count (× 109/L) 4.0 - 11.0 14.1 (7.6) 14.5 (6.3) 13.7 (8.7) 0.67
Platelet count (× 109/L) 150 - 400 254 (147) 284 (120) 226 (164) 0.03
Haemoglobin (g/dL) 12.0 - 15.0 10.2 (8.5) 9.3 (2.1) 11.0 (11.5) 0.38
Serum albumin (g/L) 35 - 50 23.7 (6.8) 26.6 (7.0) 21.3 (5.7) 0.001
C-reactive protein (mg/L) <5 177 (101) 161 (97) 191 (104) 0.20
Creatinine (µmol/L) <90 217 (464) 125 (188) 227 (236) 0.04
ALT (U/L) 5 - 40 112 (323) 99 (374) 122 (281) 0.76
SD = standard deviation; P/F ratio = arterial partial oxygen pressure to inspired fractional oxygen concentration ratio; ALT = alanine transaminase.
248       March 2021, Vol. 111, No. 3
RESEARCH
The need for mechanical ventilation in criti-
cally ill patients with TB is associated with 
increased mortality and prolonged ICU and 
hospital stays.[10] Tatar et al.[11] reported a 
mortal ity rate of 80.5% in 36 of 40 patients 
requiring mechanical ventilation in an ICU 
in Turkey, while in India, an ICU mortality 
rate of 44% was observed in 57 mechanically 
ventilated patients.[10] We previously reported 
ICU mortality and hospital mortality of 
44% and 59%, respectively.[2] The lower ICU 
(27%) and in-hospital mortality rate (52.5%) 
observed in the present study may in part be 
attributed to the recent introduction of the 
Xpert MTB/RIF as a rapid diagnostic test in 
the ICU, reducing the delay to diagnosis and 
treatment, which is a well-known risk factor 
for TB mortality.[12]
Factors significantly associated with 
mortality in the present study included a 
higher APACHE II score, hypolbuminaemia 
and thrombocytopenia, concurring with 
previous studies.[2,10,11,13] Moreover, Tatar et 
al.[11] and Ryu et al.[14] identified an APACHE 
II score of >18 and >20, respectively, as being 
predictive of death. The mean APACHE II 
score of 23.8 (21.2% for survivors v. 26.3% 
for non-survivors) in our study highlights 
the high disease acuity in our cohort, a 
finding consistent with other studies with 
predominantly mechanically ventilated 
patients.[2,11]
The association between renal failure 
and TB-related mortality remains conflic-
ting.[17,18] We identified renal failure to 
be predictive of mortality in accordance 
with some, but not all, studies.[2,15,16] In 
contrast to previous reports, we did not 
find a significant correlation with multilobar 
involvement on the chest radiograph 
and mortality.[17,18] The vast majority of 
our patients had multilobar involvement 
on admission, which may explain this 
observation. However, the presence of lobar 
consolidation was found to be negatively 
associated with mortality. Additionally, we 
confirmed the lack of association between 
radiographic evidence of cavitation and 
mortality, as previously described.[4] Septic 
shock was a strong predictor of mortality in 
our study. This is not surprising, considering 
the high mortality related to both 
mycobacterial and non-mycobacterial septic 
shock. Kethireddy et al.[19] reported a 79% 
mortality rate in patients with mycobacterial 
septic shock compared with those with 
non-mycobacterial septic shock (49.7%) 
in a multinational study.[19] Duro et al.[20] 
reported a significant association between 
severe sepsis/septic shock and mortality 
(p=0.049; OR 8.5 (95% CI 0.931 - 77.598)) in 
39 patients in Portugal.
Our study highlights the presence 
of any form of immunosuppression 
as a significant predictor of mortality. A 
contributing explanation for the poor out-
comes observed in these patients may be 
the atypical radiographic presentation 
of TB, potentially resulting in delayed 
diagnosis and commencement of anti-TB 
treatment. Approximately one-third of our 
patients were co-infected with HIV, a factor 
that did not contribute to mortality. This 
is in line with recent literature, possibly 
reflecting improving standards of care in 
this population.[20,21] The lack of association 
between mortality and HIV infection in our 
study may additionally be explained by the 
fact that our non-HIV patients had a similar 
level of disease acuity and a high mortality 
rate. Although poorer outcomes have been 
reported in HIV-infected patients with a low 
CD4 count in critical illness,
[22] TB itself may 
significantly reduce the CD4 count, with 
subsequent recovery after treatment.[23] 
TB-related ARDS was not significantly 
associated with mortality in the present 
study, in keeping with our previous report. [2] 
Additionally, we found no association 
between a P/F ratio <200 mmHg and 
in-hospital mortality. This finding is 
in concordance with several studies that 
have shown that the P/F ratio is not an 
independent predictor of mortality at the 
onset of ARDS.[24,25] A plausible explanation 
may be that the P/F ratio is a highly variable 
parameter, depending on the fraction of 
inspired oxygen and ventilator strategy 
utilised. Standardisation of ventilation 
strategies may improve its discriminatory 
power.[25] Early initiation of empirical TB 
treatment, in view of the high burden of TB 

















Revised 4-point severity-of-illness score
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Table 4. Mortality rates according to the 6-point severity-of-illness score




(N=41), n Mortality, % 
≤2 28 19 9 32.1
3 16 6 10 62.5
≥4 32 12 22 68.8
<3 28 19 9 32.1
≥3 50 18 32 64.0
Table 5. Mortality rates according to the revised 4-point severity-of-illness score




(N=41), n Mortality, %
≤1 23 18 5 21.7
2 18 11 7 38.9
3 25 6 19 76.0
4 12 2 10 83.3
≤2 41 29 12 29.3
≥3 37 8 29 78.4
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in our country, combined with earlier diagnosis utilising nucleic acid 
testing, may explain the lack of a significant association between the 
presence of TB treatment on admission and mortality in our cohort.
Study strengths and limitations
Our study has certain strengths. Unlike most current TB studies, 
which are retrospective, we prospectively enrolled a large number 
of patients in a single centre over a relatively short period of time, 
ensuring a consistent standard of care and limiting the impact of 
changes in critical care practice that occur over years. The simplicity 
and lack of a complex weighted scoring system of the revised 4-point 
score may lend itself to its use at all levels of care to develop strategies 
to improve outcome in the ICU. Future prospective research is 
needed to properly validate the revised 4-point score.
Our study may have some limitations. Resource constraints 
may have led to a selection bias towards patients with perceived 
better outcomes being preferentially admitted to the ICU. Delays in 
admission to the ICU, from the emergency department and other 
hospitals, may have resulted in delays in appropriate diagnosis and 
treatment and contributed to deteriorating clinical parameters.
Conclusions
The 6-point severity-of-illness score identified critically ill patients 
at increased risk of dying of TB. Moreover, we were able to derive 
and retrospectively validate a simplified 4-point score with superior 
predictive power, which may be particularly useful in a high-
incidence and resource-limited setting.
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